

Contents

List of Contributors XIX

Preface XXV

1	Synthesis, Functionalization, and Characterization	1
	<i>Jianxun Xu, Xing Lu, and Baowen Li</i>	
1.1	Introduction	1
1.2	Fullerenes and Metallofullerenes	1
1.2.1	Synthesis and Purification	2
1.2.1.1	Synthesis	2
1.2.1.2	Purification	2
1.2.2	Chemical Functionalization	3
1.2.2.1	Carbene Reaction	3
1.2.2.2	Bingel–Hirsch Reaction	4
1.2.2.3	Prato Reaction	5
1.2.2.4	Bis-Silylation	5
1.2.2.5	Diels–Alder Reaction and Benzyne Reaction	5
1.2.2.6	Singly Bonded Addition	6
1.2.2.7	Supramolecular Complexes of EMFs	6
1.2.3	Characterization	6
1.2.3.1	Synchrotron Radiation Powder Diffraction (SRPD)/Rietveld/MEM	6
1.2.3.2	Nuclear Magnetic Resonance (NMR) Spectroscopy	7
1.2.3.3	Theoretical Calculation	7
1.2.3.4	Single-Crystal X-ray Diffraction Crystallography	7
1.2.3.5	Others	8
1.2.4	Questions and Future Directions	8
1.3	Carbon Nanotubes	8
1.3.1	Synthesis	9
1.3.1.1	Arc Discharge Method	9
1.3.1.2	Laser Ablation Method	10
1.3.1.3	CVD Method	10
1.3.1.4	Synthesis of CNTs with a Defined Structure	10
1.3.2	Functionalization	11

1.3.2.1	Covalent Chemical Reactions	11
1.3.2.2	Noncovalent Modifications	11
1.3.3	Characterization	12
1.3.3.1	Microscopic Characterizations	12
1.3.3.2	Spectroscopic Characterizations	13
1.3.4	Questions and Future Directions	13
1.4	Graphene	14
1.4.1	Synthesis and Characterization	14
1.4.2	Functionalization of Graphene and Graphene Oxide	17
1.4.3	Prospects and Challenges	18
1.5	Summary and Outlook	20
	References	21
2	Identification and Detection of Carbon Nanomaterials in Biological Systems	29
	<i>Haifang Wang, Zheng-Mei Song, Yi-Fan Yang, Aoneng Cao, and Yuanfang Liu</i>	
2.1	Introduction	29
2.2	Available Techniques for Qualitative and Quantitative Determination	30
2.2.1	Optical Microscopic Observation	30
2.2.2	Electron Microscopic (EM) Observation	31
2.2.3	Raman Spectroscopic Measurement	33
2.2.4	Fluorescence Analysis	36
2.2.4.1	Intrinsic Fluorescence Analysis	36
2.2.4.2	Labeled Fluorescence Analysis	39
2.2.5	Isotope Labeling Method	39
2.2.5.1	Radioisotope Labeling	40
2.2.5.2	Stable Isotope Labeling	43
2.2.5.3	Tips for Isotopic Labeling	43
2.2.6	Chromatographic Technique	45
2.2.7	Flow Cytometry Method	45
2.2.8	Other Methods	46
2.3	Summary and Outlook	47
	Acknowledgments	48
	References	48
3	Biodistribution and Pharmacokinetics of Carbon Nanomaterials	
	<i>In Vivo</i>	55
	<i>Sheng-Tao Yang, Xiaoyang Liu, and Jingru Xie</i>	
3.1	Introduction	55
3.2	Amorphous Carbon Nanoparticles	55
3.2.1	Ultrafine Carbon Particles	56
3.2.2	Carbon Nanoparticles	58
3.2.3	Carbon Dots	59
3.3	sp ² Carbon Nanomaterials	62

3.3.1	Fullerene	62
3.3.2	Carbon Nanotubes	69
3.3.3	Carbon Nanohorns	77
3.3.4	Graphene	80
3.3.5	Graphene Quantum Dots	85
3.4	Nanodiamonds	87
3.5	Summary and Outlook	89
	Acknowledgments	90
	References	90
4	Interaction of Carbon Nanomaterials and Components in Biological Systems	97
	<i>Jian Tian and Cuicui Ge</i>	
4.1	Introduction	97
4.2	Factors Affecting Interaction	99
4.2.1	Characteristics of Carbon Nanomaterials	99
4.2.1.1	Size and Layer	99
4.2.1.2	Surface Modification and Functionalization	100
4.2.2	Biological Microenvironment	102
4.2.2.1	pH	103
4.2.2.2	Ionic Strength	104
4.2.2.3	Weak Interactions	104
4.2.2.4	Cell Selectivity	105
4.3	Interaction of Carbon Nanomaterials with Various Components in Biological Systems	107
4.3.1	Characterization and Methodology of Interaction of Carbon Nanomaterials with Components in the Biological System	107
4.3.2	Carbon Nanomaterial–Phospholipid Interaction	108
4.3.3	Carbon Nanomaterial–Protein Interaction	111
4.3.4	Carbon Nanomaterial–DNA Interaction	115
4.3.5	Carbon Nanomaterial–Cell Interaction	119
4.4	Conclusion and Perspectives	120
	References	122
5	Biomedical Applications of Carbon Nanomaterials	131
	<i>Liangzhu Feng and Zhuang Liu</i>	
5.1	Introduction	131
5.2	Biomedical Applications of Fullerenes	132
5.2.1	Fullerenes as Antioxidants and Neuroprotective Agents	132
5.2.2	Fullerenes as Antitumor Agents	134
5.2.3	Metallofullerenes as MRI Contrast Agent	136
5.2.4	Fullerenes for Other Applications	136
5.3	Biomedical Applications of Carbon Nanotubes	137
5.3.1	Carbon Nanotubes for Drug Delivery	138
5.3.1.1	Carbon Nanotubes for the Delivery of Small Drug Molecules	139

5.3.1.2	Carbon Nanotubes for the Delivery of Biomacromolecules	141
5.3.2	Carbon Nanotubes for Photothermal and Combined Therapies of Tumors	142
5.3.2.1	Carbon Nanotubes for Photothermal Therapy of Tumors	142
5.3.2.2	Carbon Nanotubes for Combined Therapies of Tumors	143
5.3.3	Carbon Nanotubes for Bioimaging	144
5.3.3.1	Carbon Nanotubes for Fluorescence Imaging	144
5.3.3.2	Carbon Nanotubes for Raman Imaging	145
5.3.3.3	Carbon Nanotubes for Photoacoustic Imaging	145
5.3.3.4	Carbon Nanotubes for Other Bioimaging Modalities	145
5.3.4	Carbon Nanotubes for Other Biomedical Applications	146
5.4	Biomedical Applications of Graphene	146
5.4.1	Graphene for Drug Delivery	147
5.4.1.1	Graphene for the Delivery of Small Drug Molecules	148
5.4.1.2	Graphene for the Delivery of Biomacromolecules	148
5.4.2	Graphene for Photothermal and Combined Therapies of Tumors	151
5.4.3	Graphene for Bioimaging	152
5.4.4	Graphene for Other Biomedical Applications	153
5.5	Conclusion and Perspectives	153
	Acknowledgments	154
	References	155

6 Pulmonary Effects of Carbon Nanomaterials 163

Liyang Wang, Donna C. Davidson, Vincent Castranova, and Yon Rojanasakul

6.1	Introduction	163
6.2	Physicochemical Properties of Carbon Nanomaterials	164
6.2.1	Types of Carbon Nanomaterials	165
6.2.2	Effects of Size	165
6.2.3	Effects of Agglomeration State	166
6.2.4	Aspect Ratio Considerations	168
6.2.5	Surface Modifications	168
6.3	Fate of Pulmonary Exposed Carbon Nanoparticles (Deposition, Distribution, Translocation, and Clearance)	169
6.3.1	Deposition and Distribution of Carbon Nanoparticles in the Lung	169
6.3.2	Translocation of Carbon Nanoparticles	172
6.3.3	Clearance of Carbon Nanomaterials from the Lungs	175
6.4	Carbon Nanomaterial – Induced Lung Responses	176
6.4.1	Key/Specific Target Lung Cell Types of Pulmonary-Exposed Carbon Nanoparticles	176
6.4.2	Lung Inflammation	178
6.4.3	Immune Response	179
6.4.4	Fibrosis	180
6.4.5	Genotoxicity	181

6.4.6	Cancer	182
6.4.7	Cardiovascular Effects Following Pulmonary Exposure of Carbon Nanomaterials	184
6.5	Summary	184
	Disclaimer	184
	References	189
7	Cardiovascular and Hemostatic Effects of Carbon Nanomaterials	195
	<i>Xiaoyong Deng, Cheng Li, Jiajun Wang, and Pan Chen</i>	
7.1	Background	195
7.2	Carbon Nanotubes	195
7.2.1	Hemotoxicity of CNTs	196
7.2.1.1	What Is Hemotoxicity	196
7.2.1.2	Complement System	197
7.2.1.3	Red Blood Cells	199
7.2.1.4	Hemostatic System and Coagulation/Thrombosis/Atheroma	200
7.2.2	Effects on Cardiovascular System	201
7.3	Fullerenes	203
7.3.1	Fullerenes' Escape from Lungs into Circulation	203
7.3.2	Toxicity of Fullerenes on the Cardiovascular System	204
7.4	Graphene-Related Nanomaterials	205
7.5	Conclusions and Outlook	208
	Acknowledgments	208
	References	208
8	Modulation of the Immune System by Fullerene and Graphene Derivatives	213
	<i>Ligeng Xu and Chunying Chen</i>	
8.1	Introduction	213
8.2	The Immunological Effects of Fullerene and Its Derivatives	213
8.2.1	Fullerene Derivatives Can Inhibit Inflammation via Blocking ROS Generation	213
8.2.2	Fullerene Derivatives Promote Immune Responses via Modulating Macrophages and/or Antigen Presenting Cells (APCs)	215
8.3	Immunological Effects of Graphene and Its Derivatives	222
8.3.1	Immunological Effect of Pristine Graphene	225
8.3.2	Immunological Effects of Graphene Oxide and Its Derivatives	227
8.4	Perspectives and Outlook	231
	References	234
9	Neuro-, Hepato-, and Nephrotoxicity of Carbon-based Nanomaterials	239
	<i>Jia Yao and Yongbin Zhang</i>	
9.1	Carbon-based Nanomaterials: Introduction	239
9.2	Neurotoxicity of Carbon-based Nanomaterials	240

9.2.1	Blood–Brain Barrier and BBB Penetration by Carbon-based Nanomaterials	240
9.2.2	Neurotoxicity of Carbon Nanotubes	241
9.2.3	Strategies to Reduce Neurotoxicity of Carbon Nanotubes	243
9.2.4	Neurotoxicity of Other Carbon-based Nanomaterials	244
9.3	Hepato and Nephrotoxicity of Carbon-based Nanomaterials	245
9.3.1	Carbon Nanotube Biodistribution in the Liver and Kidney	245
9.3.2	Biodistribution of Other Carbon Nanomaterials	248
9.3.3	Hepatotoxicity of Carbon Nanotubes	251
9.3.4	Carbon Nanotube Nephrotoxicity/Renal Toxicity	254
9.3.5	Hepatotoxicity and Nephrotoxicity of Other Types of Carbon-based Nanomaterials	254
9.4	Points of Consideration for Toxicity Evaluation of Carbon-based Nanomaterials	257
9.5	Summary	259
	Acknowledgments	259
	References	259
10	Genotoxicity and Carcinogenic Potential of Carbon Nanomaterials	267
	<i>Todd A. Stueckle, Linda Sargent, Yon Rojanasakul, and Liying Wang</i>	
10.1	Introduction	267
10.1.1	Engineered Nanomaterials and Long-Term Disease Risk: An Introduction	269
10.1.2	Carcinogenesis: A Multistep Process	270
10.1.2.1	Genotoxicity and Initiation	271
10.1.2.2	Promotion	272
10.1.2.3	Progression	274
10.1.3	Current Knowledge and Challenges in Carcinogenesis Studies	274
10.2	Carbon Nanomaterials: Genotoxicity and Carcinogenic Potential	275
10.2.1	Physicochemical Properties of ECNMs	275
10.2.2	Ultrafine Carbon Black	276
10.2.2.1	<i>In Vivo</i> Studies	277
10.2.2.2	<i>In Vitro</i> Studies	278
10.2.3	Carbon Nanotubes	278
10.2.3.1	<i>In Vivo</i> Studies	279
10.2.3.2	<i>In Vitro</i> Studies	291
10.2.4	Fullerenes and Derivatives	296
10.2.4.1	<i>In Vivo</i> Studies	297
10.2.4.2	<i>In Vitro</i> Studies	299
10.2.5	Graphene and Graphene Oxide	300
10.2.5.1	<i>In Vivo</i> Studies	302
10.2.5.2	<i>In Vitro</i> Studies	304
10.2.6	Carbon Nanofibers and Other Particles	307

10.2.6.1	<i>In Vivo</i> Studies	307
10.2.6.2	<i>In Vitro</i> Studies	308
10.3	Future Challenges in Carbon Nanomaterial Carcinogenesis Risk Assessment	308
10.3.1	Exposure Characterization and Fate	308
10.3.2	Dosimetry	309
10.3.3	Model Choice	310
10.3.4	Systematic Evaluation of Genotoxicity	311
10.3.5	Role of ROS and Inflammation	311
10.4	Assessment of ECNM-Induced Genotoxicity and Carcinogenesis	312
10.4.1	Recommendations for Screening ENMs for Carcinogenic Potential	312
10.4.2	Systematic Screening Paradigm and Workflow for ENM Carcinogenicity Risk Assessment	314
10.5	Concluding Remarks	316
	Acknowledgments	316
	Disclaimer	316
	References	317
11	Effect on Reproductive System of Carbon Nanomaterials	333
	<i>Ying Liu and Chunying Chen</i>	
11.1	Introduction	333
11.2	Effects of Carbon Nanomaterials on the Reproductive System	334
11.2.1	Carbon Nanotubes	335
11.2.2	Fullerene Derivatives	340
11.2.3	Carbon Black Nanoparticles	340
11.3	Insights into the Molecular Mechanisms	342
11.3.1	Potential Toxicity to the Female Reproductive System	342
11.3.2	Potential Toxicity to Male Reproduction of Carbon Nanomaterials	343
11.3.3	Potential Toxicity to Offspring of Carbon Nanomaterials	345
11.3.4	Impact on the Endocrine Organs and Hormone Biosynthesis/Metabolism	346
11.3.5	Others	348
11.4	Conclusion and Perspectives	348
	Acknowledgments	352
	References	352
12	Immunological Responses Induced by Carbon Nanotubes Exposed to Skin and Gastric and Intestinal System	357
	<i>Haiyan Xu, Jie Meng, Qiang Ma, and Xiaojin Li</i>	
12.1	Introduction	357
12.2	Biological Effects of CNTs by Dermal Exposure	358
12.2.1	<i>In Vitro</i> Assessment in Dermal-Related Cell Lines	358

12.2.2	<i>In Vivo</i> Studies on the Responses Elicited by Skin Exposed with CNTs	361
12.3	Immunological Reactions Elicited by Subcutaneous Administration of MWCNTs	362
12.3.1	Preparation and Characterization of Multiwalled Carbon Nanotubes for Uses in Studies	362
12.3.2	Distribution of Subcutaneously Injected Carbon Nanotubes	363
12.3.3	Immunological Responses Induced by Subcutaneously Injected MWCNTs	369
12.3.3.1	Macrophages Responses Exerted by MWCNTs	370
12.3.3.2	MWCNTs Attract Naïve Monocyte Macrophages Through Activating Macrophages in the Subcutis	373
12.3.3.3	Subcutaneously Injected MWCNTs Induce Complement Activation	375
12.3.3.4	Subcutaneously Injected MWCNTs Elevate Pro-inflammatory Cytokines in the Blood	376
12.4	Immunological Responses Induced by Subcutaneous Administration of MWCNTs in Tumor-Bearing Mice	377
12.4.1	MWCNTs Induce Systematic Immune Responses in Tumor-Bearing Mice	378
12.4.2	MWCNTs Upregulate Multiple Pro-inflammatory Cytokines in the Blood	378
12.4.3	MWCNTs Mediate Cytotoxicity of Lymphocytes	379
12.4.4	MWCNTs Induce Complement Activation	380
12.4.5	MWCNTs Attract Monocyte-Macrophages to Affect the Microenvironment of Tumor Mass	380
12.5	CNTs as Antigen Delivery System to Enhance Immune Responses Against Tumors	383
12.6	Immunological Responses of Gastric and Intestinal Systems Exposed to Carbon Nanotubes	386
	References	389
13	Modulation of Immune System by Carbon Nanotubes	397
	<i>Marit Ilves and Harri Alenius</i>	
13.1	Immune System	397
13.1.1	Innate Immunity Cells and Their Main Functions	398
13.1.2	Adaptive Immunity Cells and Their Main Functions	399
13.2	Carbon Nanotubes (CNTs) and Innate Immunity	400
13.2.1	Complement Activation	401
13.2.2	Macrophages	402
13.2.3	Activation of Inflammasome Complex and IL-1 β Secretion	405
13.2.4	Neutrophils	406
13.2.5	Innate Lymphoid Cells (ILCs)	408
13.2.6	Dendritic Cells	408
13.3	CNTs and Adaptive Immunity	409

13.3.1	The Effects of CNTs on Vaccine Delivery and Immunotherapy	409
13.3.2	Utilization of CNT Scaffolds in the Expanding and Modulation of Immune Cells	411
13.3.3	Immunosuppressive Effects of CNTs	413
13.4	The Effect of CNTs in Allergy and Asthma	414
13.4.1	Allergic Reactions and Their Immunological Mechanisms	414
13.4.2	Asthma	415
13.4.3	Allergic Pulmonary Inflammation Induced by Airway Exposure to CNTs	417
13.4.4	Modulation of Allergen-Induced Airway Inflammation by Exposure to CNTs	418
13.4.5	CNT in the Context of Mast Cells and Eosinophils	420
13.4.6	Role of IL-33 Pathway in CNT-Induced Allergic Responses	420
13.5	Conclusions and Future Prospects	422
	References	424
14	Carbon Dots: Synthesis, Bioimaging, and Biosafety Assessment	429
	<i>Jie Wang and Yao He</i>	
14.1	Introduction	429
14.1.1	Synthesis and Fabrication of C-dots	429
14.1.2	Bioimaging of C-dots	431
14.1.3	Biosafety Assessment of C-dots	432
14.2	Synthetic Strategies	433
14.2.1	Microwave-Assisted Methods	433
14.2.2	Hydrothermal Carbonization	434
14.2.3	Electrochemical Synthesis	437
14.2.4	Chemical Oxidation	439
14.2.5	Ultrasonication	442
14.2.6	Plasma Treatment	444
14.2.7	Laser Ablation Methods	445
14.2.8	Supported Methods	446
14.2.9	Thermal Routes	448
14.3	C-Dots-based Fluorescent Probes for Bioimaging Applications	450
14.3.1	Fluorescent Probes for Bioimaging Applications	450
14.3.2	<i>In Vitro</i> Imaging	451
14.3.3	<i>In Vivo</i> Imaging	456
14.3.4	Conclusion	462
14.4	Toxicity Assessment	462
14.4.1	<i>In Vitro</i> Toxicity Assessment	463
14.4.2	<i>In Vivo</i> Toxicity Assessment	469
14.4.3	Conclusion	475
14.5	Perspectives	477
14.5.1	Unequivocal PL Mechanism	477
14.5.2	Expanding the Spectral Coverage	478
14.5.3	QY Improvement	478

14.5.4	Bioimaging	478
14.5.5	Toxicity Assessment	479
	References	479
15	Transport in the Environment and Ecotoxicity of Carbon Nanomaterials	487
	<i>Yingying Xu and Chunying Chen</i>	
15.1	Introduction	487
15.2	Transport of Carbon Nanomaterials in the Environment	488
15.2.1	Entry of Carbon Nanomaterials into the Environment	488
15.2.2	Fate and Transformation in the Environment	488
15.2.2.1	Oxidation	488
15.2.2.2	Photochemical Transformation	490
15.2.2.3	Dissolution and Precipitation	491
15.2.2.4	Adsorption	492
15.2.2.5	Biodegradation	493
15.3	Ecotoxicity of Fullerene	494
15.3.1	Effect of Fullerene on Microorganisms	494
15.3.2	Effect of Fullerene on Animals	495
15.3.2.1	Effect of Fullerene on Invertebrates	495
15.3.2.2	Effect of Fullerene on Vertebrates	496
15.3.3	Effect of Fullerene on Plants	496
15.3.3.1	Effect of Fullerene on Algae	496
15.3.3.2	Effect of Fullerene on Higher Plants	497
15.4	Ecotoxicity of Carbon Nanotubes (CNTs)	498
15.4.1	Effect of CNTs on Microorganisms	498
15.4.2	Effect of CNTs on Animals	499
15.4.2.1	Effect of CNTs on Invertebrates	499
15.4.2.2	Effect of CNTs on Vertebrates	501
15.4.3	Effect of CNTs on Plants	502
15.4.3.1	Effect of CNTs on Algae	502
15.4.3.2	Effect of CNTs on Higher Plants	503
15.5	Ecotoxicity of Graphene	504
15.6	Conclusion and Perspectives	506
	Acknowledgments	506
	References	506
16	Exposure Scenarios in the Workplace and Risk Assessment of Carbon Nanomaterials	515
	<i>Rui Chen and Chunying Chen</i>	
16.1	Introduction	515
16.1.1	Background	515
16.1.2	Exposure Routes and Exposure Scenarios	515
16.1.3	Exposure Metrics	516
16.1.4	Occupation Exposure Limit for Carbon Nanomaterials	516

16.1.5	Strategy for Exposure Assessment of Carbon Nanomaterials	517
16.2	Potential Exposure in the Workplace	519
16.2.1	Carbon Nanotubes	519
16.2.2	Fullerenes, Metallofullerenes, and Graphenes	525
16.3	Exposure Risk Assessment and Engineering Control	527
16.3.1	Risk Assessment Strategy on Carbon Nanomaterials	527
16.3.2	Inhalation Exposure Assessment Method	529
16.3.3	Exposure Controls	530
16.4	Summary and Outlook	531
	Acknowledgments	531
	References	531
	Index	535